ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches

Guffanti, Federica; Mengoli, Ilaria; Damia, Giovanna*
Frontiers in Oncology2024-8-16DOI: 10.3389/fonc.2024.1405361
2被引3阅读
引用收藏
分享

摘要

Ovarian carcinoma (OC) still represents an insidious and fatal malignancy, and few significant results have been obtained in the last two decades to improve patient survival. Novel targeted therapies such as poly (ADP-ribose) polymerase inhibitors (PARPi) have been successfully introduced in the clinical management of OC, but not all patients will benefit, and drug resistance almost inevitably occurs. The identification of patients who are likely to respond to PARPi-based therapies relies on homologous recombination deficiency (HRD) tests, as this condition is associated with response to these treatments. This review summarizes the genomic and functional HRD assays currently used in clinical practice and those under evaluation, the clinical implications of HRD testing in OC, and their current pitfalls and limitations. Special emphasis will be placed on the functional HRD assays under development and the use of machine learning and artificial intelligence technologies as novel strategies to overcome the current limitations of HRD tests for a better-personalized treatment to improve patient outcomes.

学科与关键词

关键词
homologous recombination deficiencyovarian cancerpredictive biomarkersPARP inhibitorsplatinum drugartificial intelligence
相关
加载中…
  • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
    Zhang, Meng; Ma, Si-Cong; Tan, Jia-Le; Wang, Jian; Bai, Xue; Dong, Zhong-Yi*; Zhang, Qing-Xue*Frontiers in Oncology, 2021, 11: 772604.被引 1
  • ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis)
    Guo, Yuanli; He, Xinxin; Tan, Yanming; Liu, Junfeng; Chen, Huadong; Huang, Yi; Zhang, Chao; Tao, Ying*; Chen, Shan*Journal of Cancer Research and Clinical Oncology, 2023, 149(17): 15839-15844.
  • Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer
    Liu, Yang; Li, Yalun; Zhang, Min-Zhe; Chen, Dan; Leng, Yang; Wang, Juan; Han, Bo-Wei*; Wang, JiCANCER GENETICS, 2023, 272: 1-6.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2024-08-16
卷期
第 14 卷
页码
1405361
DOI
10.3389/fonc.2024.1405361
成果收录
SCIE
资助标注
Italian Ministry of Health; Ministry of University; Research-MUR of Istituto di Ricerche Farmacologiche Mario Negri IRCCS - P.I. Giovanna Damia [PE00000019, CUP B43D22000710006]

作者

  • G

    Guffanti, Federica (第一作者)

  • M

    Mengoli, Ilaria

查看全部 3 位作者收起作者
  • D

    Damia, Giovanna (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417